Seeking Alpha

Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences

CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...
Seeking Alpha

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings

-- On-track to initiate IND-enabling activities for Wilson’s Disease program in 4Q 2024, with IND or CTA filing expected in 1H 2026 -- CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prime ...

LifeSci Capital initiates Prime Medicine (PRME), highlights one-and-done potential in liver and lung diseases

Prime Medicine Inc. (NASDAQ:PRME) is one of the best biotech penny stocks to buy according to analysts. On December 23, ...
Morningstar

Prime Therapeutics highlights industry-leading GLP-1 research at AMCP 2025

Prime to present seven studies and receive the 2024 JMCP Award for Excellence "Prime's second-year study on the real-world impact of GLP-1 drugs for obesity showed both low adherence and increased ...